Emcure Pharmaceuticals Ltd.
EMCURE
Rangering i aksjer
#4336
Emcure Pharmaceuticals Limited is committed to providing high-quality,... Emcure Pharmaceuticals Limited is committed to providing high-quality, cost-effective healthcare solutions to a global market. The company boasts a diverse product lineup spanning numerous medical fields, such as women's health (gynecology), anti-infectives, pain relief, nutritional supplements (vitamins, minerals, and nutrients), hematology, oncology, respiratory treatments, HIV antivirals, gastrointestinal remedies, anti-diabetics, neurological medications, and cardiovascular therapies. Notable brand names under their umbrella include Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym. Founded in 1981, Emcure Pharmaceuticals Limited is headquartered in Pune, India.
Aksjekurs
$18.87
Markedsverdi
$3.58B
Endring (1 dag)
-2.83%
Endring (1 år)
19.28%
Land
IN
Handel Emcure Pharmaceuticals Ltd. (EMCURE)
Kategori
Healthcare
P/B-forhold for Emcure Pharmaceuticals Ltd. (EMCURE)
P/B-forhold per 2026 TTM: 0
Ifølge Emcure Pharmaceuticals Ltd. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/B-forhold på 0.
P/B-historikk for Emcure Pharmaceuticals Ltd. fra 2025 til 2026
P/B-forhold ved hvert års slutt
| År | P/B-forhold | Endre |
|---|---|---|
| 2025 | 4.53 | 0.00% |
P/B-forhold for lignende selskaper eller konkurrenter
| Selskap | P/B-forhold | Forskjell i P/B-forhold | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 5.041 | - |
IN
|
